GATX (GATX) Reaches $66.48 52-Week High; Dynavax Technologies (DVAX) Has 2.06 Sentiment

January 14, 2018 - By Marguerite Chambers

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor stimulation. The company has market cap of $954.39 million. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. It currently has negative earnings. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

The stock of GATX Corporation (NYSE:GATX) hit a new 52-week high and has $70.47 target or 6.00% above today’s $66.48 share price. The 6 months bullish chart indicates low risk for the $2.55 billion company. The 1-year high was reported on Jan, 14 by If the $70.47 price target is reached, the company will be worth $152.76M more. The stock increased 2.18% or $1.42 during the last trading session, reaching $66.48. About 384,653 shares traded or 34.61% up from the average. GATX Corporation (NYSE:GATX) has risen 36.88% since January 14, 2017 and is uptrending. It has outperformed by 20.18% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 12. They expect $-0.35 EPS, up 37.50% or $0.21 from last year’s $-0.56 per share. After $-0.38 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -7.89% EPS growth.

The stock decreased 1.87% or $0.3 during the last trading session, reaching $15.75. About 2.56 million shares traded or 50.34% up from the average. Dynavax Technologies Corporation (DVAX) has declined 63.84% since January 14, 2017 and is downtrending. It has underperformed by 80.54% the S&P500.

First Light Asset Management Llc holds 1.86% of its portfolio in Dynavax Technologies Corporation for 273,930 shares. Gmt Capital Corp owns 3.06 million shares or 1.4% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 1.03% invested in the company for 374,537 shares. The California-based Eam Investors Llc has invested 0.68% in the stock. Wall Street Access Asset Management Llc, a New York-based fund reported 10,900 shares.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $199,261 activity.

GATX Corporation leases, operates, manages, and remarkets assets in the rail and marine markets in North America and internationally. The company has market cap of $2.55 billion. The firm operates in four divisions: Rail North America, Rail International, American Steamship Company , and Portfolio Management. It has a 13.81 P/E ratio. The Rail North America segment primarily leases railcars and locomotive.

Among 3 analysts covering GATX (NYSE:GATX), 0 have Buy rating, 2 Sell and 1 Hold. Therefore 0 are positive. GATX had 3 analyst reports since January 12, 2017 according to SRatingsIntel. Cowen & Co initiated it with “Market Perform” rating and $62 target in Friday, March 3 report. The stock of GATX Corporation (NYSE:GATX) earned “Sell” rating by Stifel Nicolaus on Thursday, January 12. As per Friday, June 16, the company rating was maintained by Axiom Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: